



# Erratum

**Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831**

*Sanjay Kaul*

<https://doi.org/10.2337/dc18-er03a>

In the article cited above, there are typographical errors in Table 3 with regard to the values for hospitalization for heart failure results. The results should state an incidence of 2.7% (126/4,687) with empagliflozin and 4.1% (95/2,333) with placebo, and the corresponding incidence rates should be 9.4/1,000 patient-years and 14.5/1,000 patient-years, respectively. The HR of 0.65 (95% CI 0.50, 0.85) is correct.

The online version (<https://doi.org/10.2337/dc17-0291>) has been corrected to reflect these changes.